Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/Teva settle UK Lipitor patent case

Pfizer has settled its case against Teva regarding the launch of a generic version of cholesterol lowering medication Lipitor in the UK

Pfizer has settled its case against Teva regarding the launch of a generic version of cholesterol lowering medication Lipitor (atorvastatin) in the UK.

Under the terms of the agreement Teva and the other settling parties have agreed not to sell the generic atorvastatin product in the UK before patent expiry in May 2012.

Teva said it acknowledged that Pfizer's Lipitor patent was valid and its product infringed Pfizer's rights.

Pfizer extended the drug's patent protection by six months to May 2012 in Europe, with the announcement of new paediatric data enabling the launch of a chewable grape-flavoured version of Lipitor for children in the EU by November 2011.

However, generic versions of the drug are already available in certain countries including Spain, Brazil and Mexico, with Lipitor's second quarter sales down from $2.81bn in 2010 to $2.59bn in 2011.

10th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis Medical

Conversis Medical is a translation company specialising in translation and localisation for the medical industry, particularly in clinical trial projects....

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics